T Cell Lymphomas
From the Journals
A new study suggests TYK2 is expressed in all cases of ALCL.
The Food and Drug Administration has granted orphan drug designation to CPI-613 for the treatment of peripheral T-cell lymphoma (PTCL).
A 75-year-old man presented with asymptomatic annular plaques on both arms, thighs, abdomen, and buttocks, present for several months.
More than 8 in 10 youth were still alive and free of disease 4 years after starting combinations of methotrexate and/or nelarabine with chemo.
A pediatric patient developed a secondary T-cell lymphoma during a phase 1 trial of tazemetostat.
LA JOLLA, CALIF. – Dr. Steven Horwitz says the key to preparing patients for transplant is “good remission.”
Estimates on the lifetime risk vary widely.
LA JOLLA, CALIF. – Hematologists from the Royal Marsden Hospital in London review their best practices for the hardest to treat PTCL cases.
LA JOLLA, CALIF. – The study mines data from the SEER-18 database.
LA JOLLA, CALIF. – The phase 1 trial is testing the use of a CD25 monoclonal antibody for achieving long-term remission in PTCL.